Gene Sequence Determination: Principles, Testing Methods, Sample Requirements, and Applications

Gene sequence determination (DNA sequencing) is the analytical process of establishing the precise order of nucleotides—adenine, guanine, cytosine, and thymine—within a DNA or RNA molecule, and it underpins modern molecular diagnostics, biotechnology, agriculture, and life-science research. This technical guide explains the principal sequencing platforms, sample types, testing items, quality standards, and typical applications of gene sequencing services delivered by accredited third-party laboratories. Whether you need confirmation of a single clone or a complete human genome analysis, understanding the workflow and technical criteria will help you select the right sequencing strategy.

Technical Overview

Gene sequence determination, commonly known as DNA sequencing, refers to the set of laboratory and bioinformatic procedures used to read the exact nucleotide sequence of a targeted genetic region, a full chromosome, or an entire genome. The technology was revolutionized in 1977 by the chain-termination (Sanger) method, which remains the reference standard for confirmatory sequencing of short DNA fragments. Since the mid-2000s, next-generation sequencing (NGS) platforms have enabled massively parallel sequencing of millions to billions of fragments simultaneously, dramatically reducing cost per base and turnaround time while generating data suitable for whole-genome, whole-exome, and metagenomic analyses.

A typical sequencing workflow comprises five stages: nucleic acid extraction and quantification, library or template preparation, sequencing reaction on a validated instrument, base calling and quality filtering, and bioinformatic interpretation against reference databases. Quality is controlled at every stage using metrics such as DNA integrity number (DIN), Phred quality scores (Q20/Q30), read depth, and genome coverage. Professional sequencing laboratories operate under ISO/IEC 17025 general requirements for the competence of testing laboratories, and clinical sequencing laboratories additionally align with ISO 15189 requirements for medical laboratories to ensure traceability, repeatability, and defensible reporting.

Testing Samples

Human Clinical Samples

Peripheral blood collected in EDTA anticoagulant tubes is the most common substrate for germline sequencing because it yields high-molecular-weight genomic DNA from leukocytes. Fresh-frozen tissue, formalin-fixed paraffin-embedded (FFPE) blocks, buccal swabs, and cfDNA from plasma are accepted for oncology and non-invasive applications. Clinical samples must be collected with informed consent and transported under validated temperature conditions, typically 2–8 °C for short transit times or frozen on dry ice for longer periods.

Animal and Plant Samples

Animal studies commonly use whole blood, ear notches, hair follicles, or tail-tip biopsies, while plant studies accept young leaves, seeds, or callus tissue preserved in silica gel or liquid nitrogen. Plant tissues rich in polysaccharides and polyphenols require optimized CTAB-based extraction to remove PCR inhibitors. Adequate quantity (typically ≥ 1 µg for library construction) and purity (A260/A280 ratio of 1.8–2.0) are essential for high-quality sequencing data.

Microbial Samples

Bacterial and fungal isolates submitted as pure cultures on slants or plates are standard for 16S rRNA and internal transcribed spacer (ITS) identification. Cultures must be fresh, viable, and clearly labeled with biosafety information. For uncultivable or complex communities, mixed samples such as feces, fermentation broth, or swabs can be processed directly through metagenomic DNA extraction.

Food, Agricultural, and Environmental Samples

Processed foods, feeds, seeds, and ingredients are analyzed for species authentication, GMO event detection, and pathogen screening. Environmental samples include water, soil, sludge, and air-collection filters used in microbiome and biodiversity studies. These matrices often contain humic acids and other inhibitors, so laboratories apply inhibitor-removal purification steps and internal amplification controls.

Constructed DNA Materials

Plasmids, PCR amplicons, BAC clones, and synthetic gene fragments are routinely submitted for insert verification, clone confirmation, and site-directed mutagenesis validation. PCR products should be single-band as verified by agarose gel electrophoresis, and plasmid DNA should be free of RNA contamination and at concentrations suitable for direct Sanger sequencing.

Testing Items

Gene sequence determination services are organized into distinct testing portfolios depending on the scope of the genetic information required:

• Whole genome sequencing (WGS): complete reconstruction of an organism's genomic sequence, including hard-to-assemble repetitive regions.
• Whole exome sequencing (WES): targeted capture and sequencing of all protein-coding exons for disease-gene discovery.
• Targeted panel sequencing: deep sequencing of curated gene sets associated with hereditary disease, pharmacogenomics, or cancer driver mutations.
• Mitochondrial genome sequencing: full-length analysis of the ~16.6 kb mitochondrial circle for maternal lineage and mitochondrial disorder studies.
• 16S rRNA / 18S rRNA / ITS amplicon sequencing: taxonomic profiling of bacterial, fungal, or eukaryotic communities.
• Shotgun metagenomic sequencing: species-level and functional-gene characterization of complex microbial ecosystems.
• RNA sequencing (transcriptome): quantification of gene expression, alternative splicing, and fusion transcripts.
• Sanger sequencing of single genes: bidirectional sequencing of specific amplicons, plasmid inserts, and clone verification.
• DNA barcoding for species identification: standard marker regions such as COI for animals and rbcL/matK for plants.
• Variant detection: SNP, insertion/deletion (indel), copy number variation (CNV), and structural variant (SV) analysis.

Testing Methods

Sanger Sequencing (Capillary Electrophoresis)

The chain-termination method incorporates dye-labeled dideoxynucleotides during cycle sequencing, and fragments are separated by capillary electrophoresis with fluorescence detection. It delivers read lengths of 700–1,000 bp with accuracy above 99.9%, making it the reference method for confirmatory testing, cloning verification, and sequencing of single loci such as HLA typing regions or mutation hotspots.

Sequencing by Synthesis (Short-Read NGS)

Platform-based sequencing by synthesis clonal amplifies DNA fragments on flow-cell surfaces and detects fluorescent reversible terminators in real time. Reads of 100–300 bp are generated at massive scale, achieving Q30 chemistry quality. This approach dominates WGS, WES, panel sequencing, and transcriptome projects because of its high throughput and low per-base cost.

Ion Semiconductor Sequencing

This method detects hydrogen ions released during nucleotide incorporation on semiconductor chips. It offers rapid run times and flexible chip capacity, and is frequently applied to targeted panels, microbial identification, and amplicon sequencing where fast turnaround is required.

Single-Molecule Real-Time and Nanopore Long-Read Sequencing

Long-read technologies produce reads from several kilobases to megabases in length, resolving structural variants, repeat expansions, and full-length 16S transcripts that short reads cannot span. Real-time monitoring also enables rapid pathogen outbreak surveillance and adaptive sampling strategies.

Bioinformatics and Quality Assessment

All platforms feed raw signal data into validated pipelines covering base calling, adapter trimming, read filtering, reference alignment or de novo assembly, variant calling, and functional annotation. Deliverables include FASTQ raw reads, alignment files, annotated variant tables with classification according to ACMG/AMP guidelines where clinical interpretation is requested, and genome browsers for visualization. Run acceptance criteria typically require ≥ 80–90% of bases at Q30 for clinical applications and mean target coverage meeting the validated specification, commonly 30× for germline WGS and much higher depth for low-frequency variant detection in oncology.

Applications

Gene sequence determination supports decision-making across research, clinical, industrial, and regulatory contexts:

• Clinical diagnostics: diagnosis of rare hereditary diseases, carrier screening, preimplantation genetic testing, and mitochondrial disorder evaluation.
• Oncology: tumor mutation profiling, companion diagnostic biomarker assessment, minimal residual disease monitoring, and circulating tumor DNA analysis.
• Infectious disease: pathogen identification, strain typing, antimicrobial resistance gene detection, and outbreak epidemiological tracing.
• Pharmacogenomics: genotyping of drug-metabolism genes such as CYP family loci to guide personalized dosing.
• Agriculture and breeding: marker-assisted selection, genomic selection, variety identity confirmation, and GMO event characterization.
• Food authenticity: meat, fish, and plant species verification, and detection of fraudulent substitution in processed products.
• Environmental science: soil and water microbiome profiling, biodiversity metabarcoding, and bioremediation process monitoring.
• Forensic science: human identity testing, kinship analysis, and biological trace material identification.
• Biopharmaceutical manufacturing: cell-line identity and stability testing, plasmid construct confirmation, and contaminant screening.

FAQ

How much DNA is required for sequencing?

For Sanger sequencing of PCR products, 10–50 ng of purified amplicon is generally sufficient. Short-read WGS typically requires 100–1,000 ng of high-quality genomic DNA, while long-read assemblies benefit from microgram quantities of high-molecular-weight DNA. Laboratories can often perform low-input or degraded-sample protocols upon technical consultation.

How accurate is gene sequence determination?

Sanger sequencing exceeds 99.9% per-read accuracy for confirmatory applications. Short-read NGS generates consensus accuracy above 99.99% when adequate depth is applied, because independent reads are statistically consolidated. Accuracy is documented through Phred quality scores, coverage metrics, and participation in external quality assessment schemes.

What is the typical turnaround time?

Single-gene Sanger sequencing is commonly completed within 2–5 working days. Targeted NGS panels typically require 7–14 working days, and comprehensive WGS or metagenomic projects may require 2–6 weeks depending on data volume, analysis complexity, and queue conditions.

What is the difference between Sanger sequencing and NGS?

Sanger sequencing reads a single DNA molecule population per reaction and is ideal for short, defined regions and confirmation of known variants. NGS sequences millions of fragments in parallel, enabling whole-genome scale analysis, detection of low-frequency variants, and discovery of novel mutations, but requires greater bioinformatic infrastructure.

Is genetic data kept confidential?

Accredited third-party laboratories apply strict data governance policies, coded sample handling, secure data storage, and controlled access provisions compliant with applicable privacy regulations. Clinical reports are released only to the ordering clinician or authorized client contact.

Can degraded or FFPE samples be sequenced?

Yes. FFPE and other degraded samples are processed using short-amplicon designs and specialized library preparation kits. Result quality depends on DNA fragment length and the degree of formalin-induced damage, and laboratories typically perform a pre-analytical qualification assessment before committing to a full workflow.